European Medicines Agency says too early to determine need of COVID booster shot

European Medicines Agency (EMA) on July 9 said that it is too early to determine wher COVID vaccines' third dose, a booster vaccine shot, after current two vaccine shots, would be called for. y said y were confident for now that established requirement of 2 doses is enough. Meanwhile, on July 8, Pfizer and BioNTech released plans to ask European and United States regulators to authorize a booster dose after two vaccine shots. This plan was me on account of evidence of a higher risk of infection six months post-inoculation and new variant of COVID-19, named Delta variant.

Is a third dose of COVID vaccine needed?

As per reports, WHO said that y won’t know about requirement of an ditional booster shot being ministered until more data has been collected, but that it is under consideration by researchers. y also said that re is limited data available on how long vaccine doses last and whom a booster shot would be beneficial for. However, Pfizer-BioNTech plans to ask FDA for approval for COVID vaccines' third dose, after 6-8 months of second dose, after y have more data in hand. 

European Medicines Agency warns against J&J & AstraZeneca for certain individuals 

As per European Medicines Agency's Twitter handle, European Medicines Agency has also recommended dition of heart inflammation as a possible side effect of mRNA vaccines from Pfizer and Moderna. y said that myocarditis and pericarditis must be listed as possible side effects of both vaccines. As per research of US health officials, cases of se heart issues tend to occur within 14 days of getting vaccine, and more often in men, and after second dose, usually. y also vised people with Capillary Leak Syndrome (CLS), a certain rare blood disorder to avoid getting Johnson & Johnson COVID-19 vaccine. A request has been me for CLS to be ded as a side effect in AstraZeneca’s COVID-19 vaccine as well, along with a warning for Guillain-Barre syndrome. Johnson & Johnson and AstraZeneca both use different versions of a cold virus for making COVID-19 proteins to produce an immune response.

(IMAGE: AP)